Information Provided By: 
Fly News Breaks for November 26, 2019
GBT
Nov 26, 2019 | 07:42 EDT
Oppenheimer analyst Mark Breidenbach raised his price target for Global Blood Therapeutics to $100 from $94 after Oxbryta received accelerated approval from the FDA, three months ahead of the action date. Oxbryta represents a new class of disease-modifying therapy, and could potentially become a therapeutic mainstay in sickle cell anemia, Breidenbach tells investors in a research note. Further, Oxbryta's "best-case" label includes adults and adolescents 12 years and older, adds the analyst. He keeps an Outperform rating on Global Blood shares.
News For GBT From the Last 2 Days
There are no results for your query GBT
